Our findings support the effectiveness of bimekizumab in treating complex patients with involvement of difficult-to-treat areas, consistent with current real-world evidence on other IL-17 drugs for plaque psoriasis [30]. The gene discussed is IL17A; the disease is psoriasis vulgaris.